CL2018003123A1 - Terapia de combinación para el tratamiento del cáncer - Google Patents

Terapia de combinación para el tratamiento del cáncer

Info

Publication number
CL2018003123A1
CL2018003123A1 CL2018003123A CL2018003123A CL2018003123A1 CL 2018003123 A1 CL2018003123 A1 CL 2018003123A1 CL 2018003123 A CL2018003123 A CL 2018003123A CL 2018003123 A CL2018003123 A CL 2018003123A CL 2018003123 A1 CL2018003123 A1 CL 2018003123A1
Authority
CL
Chile
Prior art keywords
combination therapy
cancer treatment
cancer
treatment
therapy
Prior art date
Application number
CL2018003123A
Other languages
English (en)
Inventor
Jeffery L Keene
Dennis P Riley
Robert A Beardsley
Jr Douglas R Spitz
Melissa A Fath
Original Assignee
Galera Labs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Labs Llc filed Critical Galera Labs Llc
Publication of CL2018003123A1 publication Critical patent/CL2018003123A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

TERAPIA DE COMBINACIÓN PARA EL TRATAMIENTO DEL CÁNCER
CL2018003123A 2016-05-03 2018-10-31 Terapia de combinación para el tratamiento del cáncer CL2018003123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662331253P 2016-05-03 2016-05-03

Publications (1)

Publication Number Publication Date
CL2018003123A1 true CL2018003123A1 (es) 2019-05-03

Family

ID=60203338

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003123A CL2018003123A1 (es) 2016-05-03 2018-10-31 Terapia de combinación para el tratamiento del cáncer

Country Status (14)

Country Link
US (1) US12220420B2 (es)
EP (1) EP3452060A4 (es)
JP (2) JP2019514962A (es)
KR (2) KR20230075528A (es)
CN (1) CN109414454A (es)
AU (2) AU2017260425B2 (es)
BR (1) BR112018072560A2 (es)
CA (1) CA3022699A1 (es)
CL (1) CL2018003123A1 (es)
EA (1) EA201892510A3 (es)
IL (3) IL300085A (es)
MX (1) MX393974B (es)
SG (2) SG10202106462TA (es)
WO (1) WO2017192740A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2665984C (en) 2006-10-12 2017-02-28 Activbiotics, Inc. Superoxide dismutase mimetics for the treatment of oral mucositis
CA2849456C (en) 2011-09-26 2021-12-07 Galera Therapeutics, Llc Methods for treatment of diseases
HUE049926T2 (hu) 2015-08-11 2020-11-30 Galera Labs Llc Makrociklusos pentaazagyûrûkomplexek orális biológiai hozzáférhetõséggel
CN109414454A (zh) 2016-05-03 2019-03-01 加莱拉实验室有限责任公司 用于癌症治疗的组合疗法
US10844016B2 (en) 2016-05-03 2020-11-24 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
EP3506907B1 (en) 2016-09-01 2023-06-07 Galera Labs, LLC Combination cancer therapy with a pentaaza macrocyclic ring complex and an ascorbate compound
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
JP7388702B2 (ja) * 2017-11-15 2023-11-29 学校法人藤田学園 抗腫瘍剤及び配合剤
WO2019104579A1 (en) * 2017-11-30 2019-06-06 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
GB201800733D0 (en) * 2018-01-17 2018-02-28 Cambridge Entpr Ltd Cancer
IL276407B2 (en) * 2018-01-31 2025-01-01 Galera Labs Llc Combination cancer therapy with a pentase macrocyclic ring complex and a platinum-based anticancer agent
JP7716680B2 (ja) * 2018-01-31 2025-08-01 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
WO2019232648A1 (en) * 2018-06-08 2019-12-12 Atomic Energy Of Canada Limited / Énergie Atomique Du Canada Limitée Use of a checkpoint inhibitor in combination with ultralow dose whole body irradiation
CN109620836B (zh) * 2018-12-24 2021-05-18 陕西科技大学 一种具有抗乳腺癌作用的复方药物组合物及其用途和基于此组合物的药物
WO2021050490A1 (en) * 2019-09-13 2021-03-18 The Trustees Of Columbia University In The City Of New York Methods of enhancing radiotherapy using ferroptosis inducers as radiosensitizers
IL291989A (en) * 2019-10-10 2022-06-01 Galera Labs Llc Production method for an aqueous formulation of a manganese-containing coordination complex, formulation and treatment method
US12133846B2 (en) 2019-10-15 2024-11-05 Wayne State University Electrophilic androgen receptor (AR) antagonists for AR downregulation and ferroptosis induction in cancer cells
CN116390731A (zh) * 2020-06-02 2023-07-04 加莱拉实验室有限责任公司 五氮杂大环状环配合物与激素治疗剂的组合癌症疗法
WO2022026753A1 (en) * 2020-07-29 2022-02-03 University Of Kentucky Research Foundation Gold(iii) compounds and cancer cell-selective modulation of mitochondrial respiration and metabolism
WO2022026757A1 (en) 2020-07-29 2022-02-03 University Of Kentucky Research Foundation Accelerating repair of mucosal injury using gold(iii) compounds
WO2024026273A1 (en) * 2022-07-25 2024-02-01 Galera Labs, Llc Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex
WO2024257051A1 (en) * 2023-06-15 2024-12-19 Novocure Gmbh Compositions, systems, and methods for treating cancer using tumor treating fields (ttfields) and thioredoxin/glutathione inhibitors
KR20260009527A (ko) * 2024-07-11 2026-01-20 순천향대학교 산학협력단 오라노핀을 유효성분으로 포함하는 종양 질환 예방 또는 치료용 약학 조성물

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
KR0145953B1 (ko) 1991-07-19 1998-08-17 제임스 클리프튼 보올딩 슈퍼옥사이드의 불균화촉매로서 효과적인 질소를 포함하는 마크로사이클 릭리간드의 망간착물
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
AU706642B2 (en) 1994-04-22 1999-06-17 G.D. Searle & Co. Diagnostic image analysis with metal complexes
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
JPH0840941A (ja) 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 炎症性腸疾患治療製剤
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU6896796A (en) 1995-08-17 1997-03-12 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
US5976498A (en) 1995-08-17 1999-11-02 Neumann; William L. Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
JP2991172B2 (ja) 1997-10-24 1999-12-20 日本電気株式会社 半導体装置
JP2001521939A (ja) 1997-11-03 2001-11-13 デューク・ユニバーシティー 置換されたポルフィリン類
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US7445641B1 (en) 1999-05-27 2008-11-04 Pharmacia Corporation Biomaterials modified with superoxide dismutase mimics
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
CA2377621C (en) 1999-06-23 2009-05-19 Eric F. Bernstein Use of nitroxides in wound healing and in the prevention of photodamage
US6552010B1 (en) 1999-11-12 2003-04-22 Genelabs Technologies, Inc. Treatment of SLE with dehydroepiandrosterone
EP2343047B2 (en) 2000-02-08 2021-03-17 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
JP2004507487A (ja) 2000-08-29 2004-03-11 メファ・アクチェンゲゼルシャフト 腸疾患治療薬
US7166910B2 (en) 2000-11-28 2007-01-23 Knowles Electronics Llc Miniature silicon condenser microphone
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
EP1347773B1 (en) 2001-01-05 2010-04-14 Metaphore Pharmaceuticals Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
JP2004520380A (ja) 2001-01-19 2004-07-08 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター 癌治療本出願は、２００１年１月１９日に出願の仮出願番号第６０／２６２，３９０号の優先権を主張し、その全ての内容は、参照により本願明細書に援用したものとする。
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
EP1405066B1 (en) 2001-03-02 2015-06-17 Galera Therapeutics LLC Chromatography of metal complexes
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
US20050222250A1 (en) 2002-04-16 2005-10-06 Mohiaddin Rezvani Curcumin for the prevention and/or treatment of tissue damage
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US6781231B2 (en) 2002-09-10 2004-08-24 Knowles Electronics Llc Microelectromechanical system package with environmental and interference shield
US6798047B1 (en) 2002-12-26 2004-09-28 Amkor Technology, Inc. Pre-molded leadframe
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
FR2863892B1 (fr) 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
KR20060135922A (ko) 2004-03-29 2006-12-29 이노텍 파마슈티컬스 코포레이션 피리딜 치환된 포르피린 화합물 및 이의 사용 방법
US7262498B2 (en) 2004-10-19 2007-08-28 Hewlett-Packard Development Company, L.P. Assembly with a ring and bonding pads formed of a same material on a substrate
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US7776889B2 (en) 2005-03-31 2010-08-17 Schering Corporation Spirocyclic thrombin receptor antagonists
CN2870352Y (zh) 2005-12-23 2007-02-14 瑞声声学科技(深圳)有限公司 微机电系统传声器扣合式封装结构
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
CA2665984C (en) 2006-10-12 2017-02-28 Activbiotics, Inc. Superoxide dismutase mimetics for the treatment of oral mucositis
TWI333264B (en) 2007-01-10 2010-11-11 Advanced Semiconductor Eng Packaging structure and method of mems microphone
CA2705761C (en) 2007-11-14 2016-04-26 Kereos, Inc. Super-oxide dismutase mimetics
EP2259776A4 (en) 2008-02-29 2011-03-16 Eagle Pharmaceuticals Inc USEFUL TOPOTECAN SOLUTIONS
US20090257979A1 (en) 2008-04-15 2009-10-15 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
EP2296645B1 (en) * 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
PL2349245T3 (pl) * 2008-10-29 2017-07-31 Istituto Superiore di Sanità Leczenie utajonego zakażenia wirusem hiv-1 za pomocą auranofiny lub tritlenku diarsenu
EP2545073B1 (en) 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
US20120207687A1 (en) 2011-01-14 2012-08-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Topical formulations of targeted nitroxide agents
CA2849456C (en) * 2011-09-26 2021-12-07 Galera Therapeutics, Llc Methods for treatment of diseases
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
FR3030240B1 (fr) 2014-12-23 2017-07-28 Oreal Procede de traitement des fibres keratiniques avec une composition comprenant un acide amine
HUE049926T2 (hu) 2015-08-11 2020-11-30 Galera Labs Llc Makrociklusos pentaazagyûrûkomplexek orális biológiai hozzáférhetõséggel
US20180214583A1 (en) 2015-08-12 2018-08-02 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
CN109414454A (zh) 2016-05-03 2019-03-01 加莱拉实验室有限责任公司 用于癌症治疗的组合疗法
EP3506907B1 (en) 2016-09-01 2023-06-07 Galera Labs, LLC Combination cancer therapy with a pentaaza macrocyclic ring complex and an ascorbate compound
WO2018125862A1 (en) 2016-12-27 2018-07-05 Soon Kap Hahn Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles
AU2018221043A1 (en) 2017-02-15 2019-09-12 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
IL276407B2 (en) 2018-01-31 2025-01-01 Galera Labs Llc Combination cancer therapy with a pentase macrocyclic ring complex and a platinum-based anticancer agent
WO2024026273A1 (en) 2022-07-25 2024-02-01 Galera Labs, Llc Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex

Also Published As

Publication number Publication date
IL262661B (en) 2022-03-01
JP2019514962A (ja) 2019-06-06
US12220420B2 (en) 2025-02-11
AU2023204318A1 (en) 2023-07-27
SG10202106462TA (en) 2021-07-29
AU2017260425B2 (en) 2023-04-06
IL290149A (en) 2022-03-01
BR112018072560A2 (pt) 2019-02-19
IL262661A (en) 2018-12-31
US20190151331A1 (en) 2019-05-23
EP3452060A4 (en) 2020-01-01
AU2017260425A1 (en) 2018-11-22
KR20180132939A (ko) 2018-12-12
CA3022699A1 (en) 2017-11-09
JP2023036950A (ja) 2023-03-14
MX2018013354A (es) 2019-02-20
MX393974B (es) 2025-03-24
EA201892510A2 (ru) 2019-06-28
EA201892510A3 (ru) 2019-09-30
IL300085A (en) 2023-03-01
EP3452060A2 (en) 2019-03-13
WO2017192740A2 (en) 2017-11-09
SG11201809606YA (en) 2018-11-29
CN109414454A (zh) 2019-03-01
KR20230075528A (ko) 2023-05-31

Similar Documents

Publication Publication Date Title
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
ECSP17073743A (es) Moduladores de k-ras
IL290149A (en) Combined treatment for cancer
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
IL249065A0 (en) Combination therapies for the treatment of cancer
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
IL284875A (en) Lasofoxifene treatment of breast cancer
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
ECSP17015977A (es) Terapia de combinacion
IL258521B1 (en) Combination therapy for the treatment of cancer
MX2018010993A (es) Derivados de icariina e icaritina.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
PT3622953T (pt) Tratamento combinado do cancro
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2019009304A (es) Tratamiento para el cancer.
UY36286A (es) Tratamientos médicos basados en anamorelina
EP3413927A4 (en) CANCER THERAPY
IL261195B (en) Combined treatment for ovarian cancer
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
IL281845A (en) Combination therapy for the treatment of cancer
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도